Scholarlink

<p>Transcatheter aortic valve replacement is a key intervention for high-risk patients with severe aortic stenosis. Myval, a newer transcatheter heart valve (THV), shows promise, but a comprehensive comparison with other THVs is lacking. This study evaluates the safety and efficacy of Myval compared with contemporary THVs. A systematic review and meta-analysis of six studies involving 2335 patients was performed. Primary outcomes included all-cause mortality, cardiovascular mortality, new permanent pacemaker implantation (PPI), device success, early safety, acute kidney injury, stroke, vascular complications, and valve regurgitation. Myval was associated with significantly lower rates of new PPI (RR, 0.62; 95% CI 0.45–0.86; P = .004), higher rates of device success (RR, 1.08; 95% CI 1.01–1.16; P = .02), and early safety (RR, 1.15;&#xa0;95% CI 1.05–1.27;&#xa0;P = .003) compared with contemporary THVs. No significant differences were observed in all-cause mortality, cardiovascular mortality, acute kidney injury, stroke, vascular complications, and valve regurgitation. Myval may offer better short-term outcomes in terms of new PPI, device success, and early safety compared with contemporary THVs. Larger, prospective studies with longer follow-ups are needed to confirm these findings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparative outcomes of Myval versus contemporary transcatheter heart valves: a systematic review and meta-analysis

  • 期刊论文

  • 发表日期：

    2025年6月21日

查看全文
  • Mustafa Bilal Ozbay,
  • Serhat Degirmen,
  • Aysenur Gullu,
  • Bede Nnaemeka Nriagu,
  • Yasin Ozen,
  • Ozlem Ozcan Celebi,
  • Cagri Yayla

摘要

Transcatheter aortic valve replacement is a key intervention for high-risk patients with severe aortic stenosis. Myval, a newer transcatheter heart valve (THV), shows promise, but a comprehensive comparison with other THVs is lacking. This study evaluates the safety and efficacy of Myval compared with contemporary THVs. A systematic review and meta-analysis of six studies involving 2335 patients was performed. Primary outcomes included all-cause mortality, cardiovascular mortality, new permanent pacemaker implantation (PPI), device success, early safety, acute kidney injury, stroke, vascular complications, and valve regurgitation. Myval was associated with significantly lower rates of new PPI (RR, 0.62; 95% CI 0.45–0.86; P = .004), higher rates of device success (RR, 1.08; 95% CI 1.01–1.16; P = .02), and early safety (RR, 1.15; 95% CI 1.05–1.27; P = .003) compared with contemporary THVs. No significant differences were observed in all-cause mortality, cardiovascular mortality, acute kidney injury, stroke, vascular complications, and valve regurgitation. Myval may offer better short-term outcomes in terms of new PPI, device success, and early safety compared with contemporary THVs. Larger, prospective studies with longer follow-ups are needed to confirm these findings.